[HTML][HTML] Circulating tumor cell–based molecular classifier for predicting resistance to abiraterone and enzalutamide in metastatic castration-resistant prostate cancer
While circulating tumor cell (CTC)–based detection of AR-V7 has been demonstrated to
predict patient response to second-generation androgen receptor therapies, the rarity of AR …
predict patient response to second-generation androgen receptor therapies, the rarity of AR …
Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.
JS Chung, Y Wang, J Henderson, U Singhal… - Neoplasia (New York …, 2019 - europepmc.org
While circulating tumor cell (CTC)–based detection of AR-V7 has been demonstrated to
predict patient response to second-generation androgen receptor therapies, the rarity of AR …
predict patient response to second-generation androgen receptor therapies, the rarity of AR …
Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
JS Chung, Y Wang, J Henderson… - … (New York, NY), 2019 - pubmed.ncbi.nlm.nih.gov
While circulating tumor cell (CTC)-based detection of AR-V7 has been demonstrated to
predict patient response to second-generation androgen receptor therapies, the rarity of AR …
predict patient response to second-generation androgen receptor therapies, the rarity of AR …
[HTML][HTML] Circulating Tumor Cell–Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate …
JS Chung, Y Wang, J Henderson… - … (New York, NY), 2019 - ncbi.nlm.nih.gov
While circulating tumor cell (CTC)–based detection of AR-V7 has been demonstrated to
predict patient response to second-generation androgen receptor therapies, the rarity of AR …
predict patient response to second-generation androgen receptor therapies, the rarity of AR …
Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.
JS Chung, Y Wang, J Henderson, U Singhal… - Neoplasia (New York …, 2019 - europepmc.org
While circulating tumor cell (CTC)–based detection of AR-V7 has been demonstrated to
predict patient response to second-generation androgen receptor therapies, the rarity of AR …
predict patient response to second-generation androgen receptor therapies, the rarity of AR …